#RNA

www.cell.com

https://www.cell.com/cell/fulltext/S0092-8674(26)00519-2

No description available

www.cell.com

https://www.cell.com/cell/fulltext/S0092-8674(26)00275-8

No description available

www.cell.com

https://www.cell.com/ajhg/fulltext/S0002-9297(26)00196-5

No description available

www.cell.com

https://www.cell.com/cell/fulltext/S0092-8674(26)00346-6

No description available

www.cell.com

https://www.cell.com/cell/fulltext/S0092-8674(26)00637-9

No description available

www.cell.com

https://www.cell.com/cell/fulltext/S0092-8674(26)00511-8

No description available

doi.org

Leveraging nanoparticle protein corona to advance plasma proteome profiling | Nature Communications

The blood plasma proteome is a rich reservoir of potential biomarkers, yet its analysis is hindered by a protein concentration dynamic range exceeding ten orders of magnitude. Traditional fractionation and enrichment methods often present limitations in detecting rare proteins masked by the presence of abundant proteins. A promising frontier technology has emerged to overcome such limitations: leveraging nanoparticle protein coronas to enrich low-abundance plasma proteins and unveil previously inaccessible layers of the proteome. This Perspective highlights the capabilities of the protein corona technology in enhancing proteome coverage, addresses its current limitations and outlines future directions in proteoform analysis and causal inference. Proteomics has long suffered from artifacts and effects due to the wide range of protein concentrations. Here, the authors offer a perspective on the use of nanoparticles to enhance the detection of low-abundance proteins by using the formation

www.cell.com

https://www.cell.com/cell/fulltext/S0092-8674(26)00341-7

No description available

doi.org

Cell polarity control by an unconventional G-protein complex in bacteria | Nature Communications

In Myxococcus xanthus, a predatory soil bacterium, cell polarity and motility are regulated by MglA (a small GTPase) and its regulators, MglB (a potential GAP) and RomRX (a previously proposed GEF), but their precise roles remain unclear. Using fluorescent nucleotides suitable for fluorescence anisotropy measurements, we show that RomRX does not function as a GEF but instead acts as an effector binding MglAGTP. We further find, using an enzymatic model, that MglB exhibits both GAP and GEF properties depending on the local MglAGDP concentration. Additionally, RomRX, specifically RomR, effectively dissociates the MglA-MglB complex by sequestering MglB. This low-affinity interaction permits GAP activity while still partitioning the proteins in vivo, as shown by a biomimetic oil-emulsion droplet assay in a cell-sized system. A minimal mathematical model incorporating these interactions and previous findings recapitulates how dynamic interactions between these three players form an invertib

www.cell.com

https://www.cell.com/cell/fulltext/S0092-8674(26)00339-9

No description available

www.cell.com

https://www.cell.com/cell/fulltext/S0092-8674(26)00517-9

No description available

doi.org

Adaptive deep brain stimulation for dynamic gait control in Parkinson’s disease: a randomized feasibility trial | Nature Medicine

A randomized crossover study of five patients with Parkinson’s disease (PD) demonstrates that gait-synchronized adaptive deep brain stimulation is feasible and safe, and reduces falls compared with continuous stimulation. Gait dysfunction in PD is a major source of disability and is often insufficiently treated by continuous deep brain stimulation (cDBS). Although adaptive DBS (aDBS) has shown efficacy for other motor symptoms using β-based, state-driven neural signals, gait is a dynamic, cyclical behavior that may require temporally precise modulation. Here we evaluated a behavior-contingent aDBS approach that synchronizes stimulation to gait phase. We reported a single-center, blinded, randomized, crossover study evaluating the feasibility of identifying patient-specific biomarkers to drive aDBS. The primary outcome was feasibility of successful identification of gait-phase biomarkers to implement aDBS. Five participants with PD undergoing pallidal DBS and subdural electrode paddle i